( 30 ) http:///?disease_id=26
Oral Contraceptives on Worst . The pill can cause many adverse effects. Some of them are merely a nuisance, while others can be life-threatening. The pill can cause headaches, bloating, nausea, irregular bleeding and spotting, breast tenderness, weight gain, or vision changes. Other more serious adverse effects that can occur from a few months to a few years after starting oral contraceptives include high blood pressure, gallbladder disease, liver tumors, depression, and metabolic disorders, such as diabetes. Temporary infertility has been associated with the period of time right after pill use is stopped. But the two most dangerous risks associated with taking birth control pills are blood clots and cancer.
By SDS-PAGE and peptide mass fingerprinting, Ishitani et al. (2003) characterized human embryonic kidney cell nuclear proteins that interacted with purified AF-1 of AR. Proteins that interacted with AF-1 included nuclear RNA-binding protein NRB54 (NONO; 300084 ), polypyrimidine tract-binding protein-associated splicing factor (PSF, or SFPQ; 605199 ), paraspeckle protein-1 (PSP1, or PSPC1; 612408 ), and PSP2 (RBM14; 612409 ), which are assumed to be involved in pre-mRNA processing. Binding of NRB54 to AF-1 was ligand dependent, and AF-1 function was potentiated by NRB54.
Forty-six subfertile men with idiopathic oligospermia were randomly assigned to 6 months of treatment with a placebo, clomiphene citrate (25 or 50 mg/day), mesterolone (100 mg/day), or pentoxifylline (1200 mg/day) or 4 months of testosterone enanthate treatment (100 or 250 mg on alternate weeks). Treatment with the placebo, mesterolone, pentoxifylline, and testosterone rebound therapy did not result in a significant increase in the mean sperm concentration or pregnancy in the partners. Clomiphene citrate at both dosages significantly increased the mean sperm concentration without improving sperm motility or morphology during the 6-month treatment period. Pregnancy rates of % and % were observed in partners of men receiving clomiphene citrate 25 mg/day and 50 mg/day, respectively. This study also illustrates the difficulties in identifying suitable patients for and assessing the efficacy of different treatment regimens.